Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer ➜ Over Stichting PSMA forum ➜ Word donateur ➜ Sponsoren ➜ Vergaderingen ➜ Links ➜ Richtlijnen en protocollen ➜ Landelijke samenwerking ➜ Publicaties ➜ (Pers)berichten ➜ Filmpjes ➜ Contact
